Actemra
DOSING GUIDE

A guide to assist healthcare professionals with the dose preparation and administration of Actemra therapy in patients with:

- Rheumatoid Arthritis [RA, Intravenous]
- Polyarticular Juvenile Idiopathic Arthritis (also referred to as Juvenile Idiopathic Polyarthritis) [Intravenous]
- Systemic Juvenile Idiopathic Arthritis [Intravenous]
- Actemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation [Intravenous]

[Health Authority Approval Date: October, 2024]

Contents

This Actemra Dosing Guide [is a requirement of the Actemra product license and] contains important safety information that you need to be aware of when administering Actemra. This Actemra Dosing Guide must be read together with the Actemra Healthcare Professional and Patient Brochures [available online at [insert website address] and the Actemra Labeling/Summary of Product Characteristics that comes with Actemra (and is also available on [insert website address]) as it contains important information about Actemra.

Please read this information carefully before administering the product.

Actemra IV (Actemra 20 mg/ml concentrate for solution for infusion):

Actemra, in combination with methotrexate (MTX), is indicated for:

- The treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.
- The treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying antirheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.
- In these patients, Actemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.
- Actemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.

Actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. Actemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.

Actemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX.

Actemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Actemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

Prior to starting treatment with Actemra:

- It is important that you review the pre-administration checklist found in the Patient Brochure: ***Before starting treatment with Actemra® (tocilizumab)*** with your patient, the patient's parents/guardians, or both.
- Allow ample time to discuss any questions your patient, the patient's parents/guardians, or both may have.

- It is important that you review the information contained within the *Healthcare Professional Brochure* for Actemra® (tocilizumab) intravenous (IV) formulations and the Patient Brochure: ***Before starting treatment with Actemra® (tocilizumab)*** with your patient, the patient's parents/guardians, or both. These will help them understand what they may expect from the treatment of the patient's condition with Actemra.

For full information, see the Summary of Product Characteristics (SmPC) and the Actemra Package Leaflet: Information for the user, which can be found on the www.pharm.am website.

Actemra Patient Brochures and other information can be requested from the responsible of the product: Gayane Ghazaryan, Local person for Pharmacovigilance for Hoffmann-La Roche products in Armenia Acti Group LLC., via mob.: +374 91 796688 or email address: gayaneh.ghazaryan@gmail.com; or Nune Karapetyan, Local backup for Pharmacovigilance of Roche Products in Armenia, via mob.: +374 91 721153 or email address: nune.karapetyan.roche@gmail.com..

If you have questions or concerns, please visit [insert local affiliate Website] or call [insert affiliate contact number].

PART I – INTRAVENOUS (IV) ADMINISTRATION OF ACTEMRA BY INFUSION

This guide will walk you through the Actemra infusion process in 6 steps

1 WEIGH PATIENT AND CALCULATE ACTEMRA DOSE BASED ON INDICATION

Actemra dosing is calculated based on each patient's weight and the indication for which they are treated. The treatment frequency varies by indication. Verify the patient's weight and indication, then locate it on the chart to find the corresponding dose and recommended vial combination.

If the patient's dose has been calculated prior to the infusion date, take his or her weight to make sure that it has not changed from the time of the original calculation to require a change in dose. If the patient's weight has changed, contact the prescriber to discuss whether a dosing change is needed. Refer to the chart to check whether a dosing adjustment is necessary.

Once the dose is calculated, choose the vial combination of Actemra that best matches the patient's needs. Actemra is available in three different dosing vials:

 400 mg (20 ml) vials 200 mg (10 ml) vials  80 mg (4 ml) vials

Inspect the vials for particulate matter and discolouration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles should be used.

RA: Dosing Preparation and Administration Guide with Actemra IV

Actemra IV dosing in RA patients is calculated based on each patient's weight as follows:

For the 8 mg/kg dose: Patient weight (kg) x 8 (mg/kg) = Actemra 8 mg

For individuals whose body weight is more than 100 kg, doses exceeding 800 mg per infusion are not recommended.

8 mg/kg dose

Weight (kg)	Weight (lbs)	Dose (mg)	Dose (mL)	Vial combinations
50	110.0	400	20.0	1 × 400 mg
52	114.4	416	20.8	1 × 400 mg + 1 × 80 mg
54	118.8	432	21.6	1 × 400 mg + 1 × 80 mg
56	123.2	448	22.4	1 × 400 mg + 1 × 80 mg
58	127.6	464	23.2	1 × 400 mg + 1 × 80 mg
60	132.0	480	24.0	1 × 400 mg + 1 × 80 mg
62	136.4	496	24.8	1 × 200 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
64	140.8	512	25.6	1 × 200 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
66	145.2	528	26.4	1 × 400 mg + 1 × 80 mg + 1 × 80 mg
68	149.6	544	27.2	1 × 400 mg + 1 × 80 mg + 1 × 80 mg
70	154.0	560	28.0	1 × 400 mg + 1 × 80 mg + 1 × 80 mg
72	158.4	576	28.8	1 × 400 mg + 1 × 200 mg
74	162.8	592	29.6	1 × 400 mg + 1 × 200 mg
76	167.2	608	30.4	1 × 400 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
78	171.6	624	31.2	1 × 400 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
80	176.0	640	32.0	1 × 400 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
82	180.4	656	32.8	1 × 400 mg + 1 × 200 mg + 1 × 80 mg
84	184.8	672	33.6	1 × 400 mg + 1 × 200 mg + 1 × 80 mg
86	189.2	688	34.4	1 × 400 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
88	193.6	704	35.2	1 × 400 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
90	198.0	720	36.0	1 × 400 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
92	202.4	736	36.8	1 × 400 mg + 1 × 200 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
94	206.8	752	37.6	1 × 400 mg + 1 × 200 mg + 1 × 80 mg + 1 × 80 mg + 1 × 80 mg
96	211.2	768	38.4	1 × 400 mg + 1 × 400 mg
98	215.6	784	39.2	1 × 400 mg + 1 × 400 mg
≥100	≥220.0	800	40.0	1 × 400 mg + 1 × 400 mg

pJIA: Dosing Preparation and Administration Guide with Actemra IV

Dosing should take place at 4-week intervals.

A change in dose of 8mg/kg or 10 mg/kg should only be based on a consistent change in the patient's body weight over time (e.g., within 3 weeks). If the patient's weight has changed, contact the prescriber to discuss whether a dosing change is needed. Refer to the chart to check whether a dosing adjustment is necessary.

Actemra IV dosing in pJIA patients is calculated based on each patient's weight as follows:

For patients weighing <30 kg: Patient's weight (kg) x 10 mg/kg = Actemra dose

For patients weighing ≥30 kg: Patient's weight (kg) x 8 mg/kg = Actemra dose

	Weight (kg)	Weight (lbs)	Dose (mg)	Dose (ml)	Vial combinations
10 mg/kg	10	22.0	100	5.0	1 + 1
	12	26.4	120	6.0	1 + 1
	14	30.8	140	7.0	1 + 1
	16	35.2	160	8.0	1 + 1
	18	39.6	180	9.0	1
	20	44.0	200	10.0	1
	22	48.4	220	11.0	1 + 1 + 1
	24	52.8	240	12.0	1 + 1 + 1
	26	57.2	260	13.0	1 + 1
	28	61.6	280	14.0	1 + 1
8 mg/kg	30	66.0	240	12.0	1 + 1 + 1
	32	70.4	256	12.8	1 + 1
	34	74.8	272	13.6	1 + 1
	36	79.2	288	14.4	1 + 1 + 1 + 1
	38	83.6	304	15.2	1 + 1 + 1 + 1
	40	88.0	320	16.0	1 + 1 + 1 + 1
	42	92.4	336	16.8	1 + 1 + 1
	44	96.8	352	17.6	1 + 1 + 1
	46	101.2	368	18.4	1
	48	105.6	384	19.2	1
	50	110.0	400	20.0	1
	52	114.4	416	20.8	1 + 1 + 1 + 1
	54	118.8	432	21.6	1 + 1 + 1 + 1
	56	123.2	448	22.4	1 + 1
	58	127.6	464	23.2	1 + 1
	60	132.0	480	24.0	1 + 1
	62	136.4	496	24.8	1 + 1 + 1 + 1 + 1
	64	140.8	512	25.6	1 + 1 + 1 + 1 + 1
	66	145.2	528	26.4	1 + 1 + 1
	68	149.6	544	27.2	1 + 1 + 1
	70	154.0	560	28.0	1 + 1 + 1
	72	158.4	576	28.8	1 + 1
	74	162.8	592	29.6	1 + 1
	76	167.2	608	30.4	1 + 1 + 1 + 1
	78	171.6	624	31.2	1 + 1 + 1 + 1
	80	176.0	640	32.0	1 + 1 + 1 + 1
	82	180.4	656	32.8	1 + 1 + 1
	84	184.8	672	33.6	1 + 1 + 1
	86	189.2	688	34.4	1 + 1 + 1 + 1 + 1
	88	193.6	704	35.2	1 + 1 + 1 + 1 + 1
	90	198.0	720	36.0	1 + 1 + 1 + 1 + 1
	92	202.4	736	36.8	1 + 1 + 1 + 1
	94	206.8	752	37.6	1 + 1 + 1 + 1
	96	211.2	768	38.4	1 + 1
	98	215.6	784	39.2	1 + 1
	≥100	≥220.0	800	40.0	1 + 1

sJIA: Dosing Preparation and Administration Guide with Actemra IV

Dosing should take place at 2-week intervals.

A change in dose of 8mg/kg or 12 mg/kg should only be based on a consistent change in the patient's body weight over time (e.g., within 3 weeks). If the patient's weight has changed, contact the prescriber to discuss whether a dosing change is needed. Refer to the chart to check whether a dosing adjustment is necessary.

Actemra dosing in sJIA patients is calculated based on each patient's weight as follows:

For patients weighing <30 kg: Patient's weight (kg) x 12 mg/kg = Actemra dose

For patients weighing ≥30 kg: Patient's weight (kg) x 8 mg/kg = Actemra dose

	Weight (kg)	Weight (lbs)	Dose (mg)	Dose (ml)	Vial combinations
12 mg/kg	10	22.0	120	6.0	1 + 1
	12	26.4	144	7.2	1 + 1
	14	30.8	168	8.4	1
	16	35.2	192	9.6	1
	18	39.6	216	10.8	1 + 1 + 1
	20	44.0	240	12.0	1 + 1 + 1
	22	48.4	264	13.2	1 + 1
	24	52.8	288	14.4	1 + 1 + 1 + 1
	26	57.2	312	15.6	1 + 1 + 1 + 1
	28	61.6	336	16.8	1 + 1 + 1
8 mg/kg	30	66.0	240	12.0	1 + 1 + 1
	32	70.4	256	12.8	1 + 1
	34	74.8	272	13.6	1 + 1
	36	79.2	288	14.4	1 + 1 + 1 + 1
	38	83.6	304	15.2	1 + 1 + 1 + 1
	40	88.0	320	16.0	1 + 1 + 1 + 1
	42	92.4	336	16.8	1 + 1 + 1
	44	96.8	352	17.6	1 + 1 + 1
	46	101.2	368	18.4	1
	48	105.6	384	19.2	1
	50	110.0	400	20.0	1
	52	114.4	416	20.8	1 + 1 + 1 + 1
	54	118.8	432	21.6	1 + 1 + 1 + 1
	56	123.2	448	22.4	1 + 1
	58	127.6	464	23.2	1 + 1
	60	132.0	480	24.0	1 + 1
	62	136.4	496	24.8	1 + 1 + 1 + 1 + 1
	64	140.8	512	25.6	1 + 1 + 1 + 1 + 1
	66	145.2	528	26.4	1 + 1 + 1
	68	149.6	544	27.2	1 + 1 + 1
	70	154.0	560	28.0	1 + 1 + 1
	72	158.4	576	28.8	1 + 1
	74	162.8	592	29.6	1 + 1
	76	167.2	608	30.4	1 + 1 + 1 + 1
	78	171.6	624	31.2	1 + 1 + 1 + 1
	80	176.0	640	32.0	1 + 1 + 1 + 1
	82	180.4	656	32.8	1 + 1 + 1
	84	184.8	672	33.6	1 + 1 + 1
	86	189.2	688	34.4	1 + 1 + 1 + 1 + 1
	88	193.6	704	35.2	1 + 1 + 1 + 1 + 1
	90	198.0	720	36.0	1 + 1 + 1 + 1 + 1
	92	202.4	736	36.8	1 + 1 + 1 + 1
	94	206.8	752	37.6	1 + 1 + 1 + 1
	96	211.2	768	38.4	1 + 1
	98	215.6	784	39.2	1 + 1
	≥100	≥220.0	800	40.0	1 + 1

2 GATHER ALL NECESSARY SUPPLIES

You will need:

- Actemra, at room temperature
- Syringes and large-bore needles
- One primary infusion set
- One 100 ml or 50 ml (for patients <30kg) bag of 0.9% (9 mg/mL) sterile,non-pyrogenic sodium chloride solution for injection
- One intravenous (IV) catheter
- Gauze
- Tourniquet
- Gloves
- Alcohol/cleansing wipes

3 TAKE BASELINE ASSESSMENTS

Take baseline assessments to ensure the patient is healthy enough to receive the infusion.

Vital signs may include:

- Blood pressure
- Temperature
- Pulse

Follow the recommended baseline patient questions as described in the Actemra Healthcare Professional Brochure (Section 14 – General Recommendation) as well as the Summary of Product Characteristics (Section 4.4 – Warnings and Precautions).

4 PREPARE THE PATIENT FOR THE INFUSION

Review the Patient Brochure: ***Before starting treatment with Actemra® (tocilizumab)*** with the patient. Answer any questions he or she might have

Actemra does not require premedication

5 PREPARE THE ACTEMRA INFUSION

Actemra is a ready-mix solution and requires no reconstitution. The expiry date should always be checked before use. The Actemra concentrate for IV infusion should be diluted by a healthcare professional using aseptic technique.

- Actemra should be refrigerated for storage. However, the fully diluted Actemra solution should be allowed to reach room temperature before it is infused.
- The fully diluted Actemra solutions for infusion may be stored at 2°C–8°C or room temperature (if diluted under controlled and validated aseptic conditions) for up to 24 hours and should be protected from light.
- Actemra solutions do not contain preservatives; therefore, unused product remaining in the vials should not be used.
- **Weight-/indication-based dosing:**
    - **For RA, sJIA (>30 kg), and pJIA (>30 kg):** From a 100 ml infusion bag withdraw a volume of 0.9% (9 mg/ml) sterile, non-pyrogenic sodium chloride solution for injection equal to the volume of the Actemra solution required for the patient's dose.
    - **For sJIA and pJIA patients < 30 kg:** Use a 50ml infusion bag withdraw a volume of 0.9% (9 mg/ml) sterile, non-pyrogenic sodium chloride solution for injection equal to the volume of the Actemra solution required for the patient's dose.
- Actemra should not be infused concomitantly in the same IV line with other medications. No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of Actemra with other medications.
- Slowly add Actemra concentrate for IV infusion from each vial into the infusion bag. To mix the solution, gently invert the bag to avoid foaming.

- Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles should be diluted.
- Dispose of needle and syringe in sharps containers when finished.

6 BEGIN THE ACTEMRA INFUSION

The infusion should be administered over 60 minutes. It must be administered with an infusion set and should never be administered as an IV push or bolus.

Monitor the patient for infusion related reactions.

Once the infusion is completed, remove the catheter and dispose of all supplies properly, clean and bandage the infusion site and check the patient's vital signs.

7 RECORD YOUR INJECTION

Product traceability

In order to improve the traceability of biological medicinal products, the tradename and batch number of the administered product should be clearly recorded (or stated) in the patient file.

Call for reporting

If the patient experiences any side effects, talk to the doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly to "Centre of Drug and Medical Technology Expertise" SNCO via contacts presented below: address: RA, Yerevan 0051, 49/5 Komitas avenue, "Centre of Drug and Medical Technology Expertise" SNCO website, or (+374 60) 830073, (+374 10) 230896; or hot line: (+374 10) 200505; (+374 96) 220505; or try e-mail: vigilance@pharm.am**:**

Please report side-effects to Gayane Ghazaryan, Local person for Pharmacovigilance for Hoffmann-La Roche products in Armenia Acti Group LLC., via mob.: +374 91 796688 or email address: gayaneh.ghazaryan@gmail.com; or Nune Karapetyan, Local backup for Pharmacovigilance of Roche Products in Armenia, via mob.: +374 91 721153 or email address: nune.karapetyan.roche@gmail.com.

Also you may contact to Local Safety Responsible, Roche Georgia LLC via tel: +995 322 506284, +995 322 507284 or emailing to georgia.safety@roche.com.

For full information on all possible side effects please see the Actemra Package Leaflet, which can be found at the "Centre of Drug and Medical Technology Expertise" SNCO website, or (+374 60) 830073, (+374 10) 230896; or hot line: (+374 10) 200505; (+374 96) 220505; or try e-mail: vigilance@pharm.am.

Gayane Ghazaryan Gayaneh Ghazaryan 23-окт-2024 | 14:47 CEST
Local person for Pharmacovigilance for Hoffmann- La Roche products in Armenia, ActiGroup LLC.

Nino Ganugrava Nino Ganugrava 28-Oct-2024 | 02:28 PDT
Country Medical Director for Georgia/Armenia, Roche Georgia LLC.

[Health Authority Approval Date: October, 2024]